Inducibility or predestination? Queries and concepts around drug-free remission in rheumatoid arthritis

References

• Schett G, Emery P, Tanaka Y, et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis. 2016;75(8):1428–1437.
   PubMed Web of Science ®Google Scholar
• Burgers LE, Raza K, van der Helm-van Mil AH. Window of opportunity in rheumatoid arthritis - definitions and supporting evidence: from old to new perspectives. RMD Open. 2019;5(1):e000870.
   PubMed Web of Science ®Google Scholar
• Ajeganova S, van Steenbergen HW, van Nies JAB, et al. Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms. Ann Rheum Dis. 2016 May;75(5):867–873.
   PubMed Web of Science ®Google Scholar
• Verstappen M, Van Mulligen E, De Jong PHP, et al., DMARD-free remission as novel treatment target in rheumatoid arthritis: a systematic literature review of achievability and sustainability. RMD Open. 2020. 6(1): e001220.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):S685–99.
   PubMed Web of Science ®Google Scholar
• Verstappen M, van der Helm-van Mil AHM. Sustained DMARD-free remission in rheumatoid arthritis – about concepts and moving towards practice. Jt Bone Spine. 2022 Nov;89(6):105418.
   PubMed Web of Science ®Google Scholar
• van der Woude D, Visser K, Klarenbeek NB, et al. Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies. Rheumatology (Oxford). 2012 Jun;51(6):1120–1128.
   PubMed Web of Science ®Google Scholar
• van der Woude D, Young A, Jayakumar K, et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum. 2009 Aug;60(8):2262–2271.
   PubMedGoogle Scholar
• Kissel T, Hafkenscheid L, Wesemael TJ, et al. IgG anti–citrullinated protein antibody variable domain glycosylation increases before the onset of rheumatoid arthritis and stabilizes thereafter: a cross‐sectional study encompassing ~1,500 samples. Arthritis Rheumatol. 2022 Jul 28;74(7):1147–1158.
   PubMed Web of Science ®Google Scholar
• van Steenbergen HW, van Nies JAB, Ruyssen-Witrand A, et al. IL2RA is associated with persistence of rheumatoid arthritis. Arthritis Res Ther. 2015Sep8; 17:244. Internet
   PubMed Web of Science ®Google Scholar
• van Wesemael Mv TJ, Knevel R, van der Helm - van Mil AHM, et al. In rheumatoid arthritis, the association between anti-modified protein antibodies and long- term outcomes is dominated by the effect of anti-citrullinated protein antibodies. Lancet Rheumatol. 2022;4:e316–e317.
   Google Scholar
• Matthijssen XME, Niemantsverdriet E, Huizinga TWJ, et al., Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: a longitudinal cohort study in the Netherlands. PLoS Med. 2020. 17(9): 1–18.
   Web of Science ®Google Scholar
• Versteeg GA, Steunebrink LMM, Vonkeman HE, et al. Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice. Clin Rheumatol. 2018 May;37(5):1189–1197.
   PubMed Web of Science ®Google Scholar
• Der Linden MPM V, Le Cessie S, Raza K, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2010;62(12):3537–3546.
   PubMedGoogle Scholar
• Hashimoto M, Furu M, Yamamoto W, et al. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther. 2018 Dec 3;20(1):165.
   PubMedGoogle Scholar
• Ahmad HA, Baker JF, Conaghan PG, et al. Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with Abatacept. Arthritis Res Ther. 2022;24(1):47.
   PubMed Web of Science ®Google Scholar
• Araujo EG, Finzel S, Englbrecht M, et al. High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission. Ann Rheum Dis. 2015 Apr;74(4):655–660.
   PubMed Web of Science ®Google Scholar
• Bugatti S, Sakellariou G, Luvaro T, et al. Clinical, imaging, and pathological suppression of synovitis in rheumatoid arthritis: is the disease curable? Front Med. 2018 May 15;5. 10.3389/fmed.2018.00140
   Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Bijlsma JWJ, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010 Apr 1;69(4):631–637.
   PubMed Web of Science ®Google Scholar
• Monti S, Montecucco C, Bugatti S, et al. Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open. 2015;1(Suppl 1):e000057.
   PubMedGoogle Scholar
• Scirè CA, Lunt M, Marshall T, et al. Early remission is associated with improved survival in patients with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis. 2014 Sep;73(9):1677–1682.
   PubMed Web of Science ®Google Scholar
• Möttönen T, Hannonen P, Korpela M, et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum. 2002 Apr;46(4):894–898.
   PubMed Web of Science ®Google Scholar
• Gremese E, Salaffi F, Bosello SL, et al. Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. Ann Rheum Dis. 2013 Jun;72(6):858–862.
   PubMed Web of Science ®Google Scholar
• Van Nies JAB, Krabben A, Schoones JW, et al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis. 2014;73(5):861–870.
   PubMed Web of Science ®Google Scholar
• Niemantsverdriet E, Dougados M, Combe B, et al. Referring early arthritis patients within 6 weeks versus 12 weeks after symptom onset: an observational cohort study. Lancet Rheumatol. 2020 Jun;2(6):e332–8.
   Google Scholar
• Van Nies JAB, Tsonaka R, Gaujoux-Viala C, et al. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the leiden early arthritis clinic and ESPOIR cohorts. Ann Rheum Dis. 2015;74(5):806–812.
   PubMed Web of Science ®Google Scholar
• Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263–269.
   PubMed Web of Science ®Google Scholar
• Verstappen SMM, Jacobs JWG, Van Der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer assisted management in early rheumatoid arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007;66(11):1443–1449.
   PubMed Web of Science ®Google Scholar
• Schipper LG, Vermeer M, Kuper HH, et al. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the dutch rheumatoid arthritis monitoring registry. Ann Rheum Dis. 2012 Jun;71(6):845–850.
   PubMed Web of Science ®Google Scholar
• Markusse IM, Akdemir G, Dirven L, et al., Long-term outcomes of patients with recent-onset rheumatoid arthritis after 10 years of tight controlled treatment: a randomized trial. Ann Intern Med. 2016. 164(8): 523–531.
   PubMed Web of Science ®Google Scholar
• Kuijper TM, Luime JJ, de Jong PHP, et al. Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial. Ann Rheum Dis. 2016 Dec;75(12):2119–2123.
   PubMed Web of Science ®Google Scholar
• Burgers LE, van der Pol JA, Huizinga TWJ, et al. Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care. Arthritis Res Ther. 2019;21(1):115.
   PubMedGoogle Scholar
• Akdemir G, Heimans L, Bergstra SA, et al. Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study. Ann Rheum Dis. 2018 Jan;77(1):111–118.
   PubMed Web of Science ®Google Scholar
• Verstappen M, Niemantsverdriet E, Matthijssen XME, et al., Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis. Arthritis Res Ther. 2020. 22(1): 1–11.
   PubMed Web of Science ®Google Scholar
• Nam JL, Villeneuve E, Hensor EMA, et al. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. Ann Rheum Dis. 2014 Jun;73(6):1027–1036.
   PubMed Web of Science ®Google Scholar
• Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with Abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015 Jan;74(1):19–26.
   PubMed Web of Science ®Google Scholar
• Bijlsma JWJ, Welsing PMJ, Woodworth TG, et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet. 2016 Jul;388(10042):343–355.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL, et al. American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol (Hoboken, NJ). 2015 [2016 Jan];68(1):1–26.
   PubMed Web of Science ®Google Scholar
• Ahern MJ, Hall ND, Case K, et al. D-penicillamine withdrawal in rheumatoid arthritis. Ann Rheum Dis. 1984 Apr 1;43(2):213–217.
   PubMed Web of Science ®Google Scholar
• Baker KF, Skelton AJ, Lendrem DW, et al. Predicting drug-free remission in rheumatoid arthritis: a prospective interventional cohort study. J Autoimmun. 2019 Dec;105:102298.
   PubMed Web of Science ®Google Scholar
• Quinn MA, Conaghan PG, O’Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-m. Arthritis Rheum. 2005 Jan;52(1):27–35.
   PubMed Web of Science ®Google Scholar
• Bejarano V, Conaghan PG, Quinn MA, et al. Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis. Rheumatology. 2010 Oct 1;49(10):1971–1974.
   PubMed Web of Science ®Google Scholar
• Van Den Broek M, Lems WF, Allaart CF. BeSt practice: the success of early-targeted treatment in rheumatoid arthritis. Clin Exp Rheumatol. 2012;30(4 SUPPL.73) S35–8.
   PubMed Web of Science ®Google Scholar
• Emery P, Hammoudeh M, FitzGerald O, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med. 2014 Nov 6;371(19):1781–1792.
   PubMed Web of Science ®Google Scholar
• van Mulligen E, Weel AE, Hazes JM, et al. Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial. Ann Rheum Dis. 2020;79(9):1174–1181.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Emery P, Karis E, et al. Etanercept or methotrexate withdrawal in rheumatoid arthritis patients in sustained remission. Arthritis rheumatol. (Hoboken NJ): 2021.Vol. 73(5)759–768.
   Google Scholar
• Henaux S, Ruyssen-Witrand A, Cantagrel A, et al. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis. Ann Rheum Dis. 2018;77(4):515–522.
   PubMed Web of Science ®Google Scholar
• Lillegraven S, Paulshus Sundlisæter N, Aga A-B, et al. Effect of half-dose vs stable-dose conventional synthetic disease-modifying antirheumatic drugs on disease flares in patients with rheumatoid arthritis in remission: the arctic rewind randomized clinical trial. JAMA. 2021;325(17):1755–1764.
   PubMed Web of Science ®Google Scholar
• Kievit W, van Herwaarden N, van den Hoogen FH, et al. Disease activity-guided dose optimisation of Adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Ann Rheum Dis. 2016 Nov;75(11):1939–1944.
   PubMed Web of Science ®Google Scholar
• Vanier A, Mariette X, Tubach F, et al. Cost-effectiveness of TNF-blocker injection spacing for patients with established rheumatoid arthritis in remission: an economic evaluation from the spacing of TNF-blocker injections in rheumatoid arthritis trial. Value Heal. 2017 Apr;20(4):577–585.
   PubMed Web of Science ®Google Scholar
• van Mulligen E, Weel AE, Kuijper TM, et al. Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial. Ann Rheum Dis. 2020;79(12):1550–1556.
   PubMed Web of Science ®Google Scholar
• Krijbolder DI, Verstappen M, van Dijk BT, et al. Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet. 2022 Jul;400(10348):283–294.
   PubMed Web of Science ®Google Scholar
• Ajeganova S, Huizinga T. Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. Ther Adv Musculoskelet Dis. 2017 Oct 2;9(10):249–262.
   PubMed Web of Science ®Google Scholar
• Kuijper TM, Lamers-Karnebeek FBG, Jacobs JWG, et al. Flare rate in patients with rheumatoid arthritis in low disease activity or remission when tapering or stopping synthetic or biologic DMARD: a systematic review. J Rheumatol. 2015 Nov;42(11):2012–2022.
   PubMed Web of Science ®Google Scholar